Fig. 3
nDCB is more potent than DCB A in a human BRCA-proficient TNBC MDA-MB-231-LUC-D3H2LN model. Dose response for the 231 cell line of the combination treatment at three different ratios (B) and corresponding combination indices (C) for each ratio. Representative images of (D) treatments has been presented and survival fraction has been quantification (E). Prior treatment with DCB sensitizes 231 cells to TLZ (F) as evidenced by a shift in the IC50 value. Calculated IC50 of (G) 4T1 cell line, a murine BRCA-proficient metastatic, TNBC model, and best fit IC50 values were generated by GraphPad Version 9.5.1 from Log(inhibitor) vs. response curve. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001